ADMP Stock Overview
About the company
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Adamis Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.12 |
| 52 Week High | US$0.62 |
| 52 Week Low | US$0.099 |
| Beta | 1.26 |
| 1 Month Change | -57.15% |
| 3 Month Change | -23.72% |
| 1 Year Change | -80.17% |
| 3 Year Change | -67.49% |
| 5 Year Change | -96.60% |
| Change since IPO | -98.98% |
Recent News & Updates
Recent updates
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
Sep 30Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.
Jul 29Adamis CEO urges stock split approval, slate of directors in letter to shareholders
Jul 21Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope
Apr 13Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
Jan 20Adamis Pharmaceuticals: It's Now Or Never
Dec 02Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines
Sep 03Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares
Jun 13Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19
Jun 07Adamis pharmaceuticals gets deficiency letter from NASDAQ
May 28Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering
Jan 29Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose
Nov 16Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue
Nov 09Shareholder Returns
| ADMP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 8.2% | -1.3% | -0.3% |
| 1Y | -80.2% | -6.1% | -14.8% |
Return vs Industry: ADMP underperformed the US Pharmaceuticals industry which returned -6.1% over the past year.
Return vs Market: ADMP underperformed the US Market which returned -14.8% over the past year.
Price Volatility
| ADMP volatility | |
|---|---|
| ADMP Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ADMP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ADMP's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
Adamis Pharmaceuticals Corporation Fundamentals Summary
| ADMP fundamental statistics | |
|---|---|
| Market Cap | US$19.98m |
| Earnings (TTM) | -US$26.20m |
| Revenue (TTM) | US$4.76m |
4.2x
P/S Ratio-0.8x
P/E RatioIs ADMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADMP income statement (TTM) | |
|---|---|
| Revenue | US$4.76m |
| Cost of Revenue | US$6.19m |
| Gross Profit | -US$1.43m |
| Other Expenses | US$24.77m |
| Earnings | -US$26.20m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.16 |
| Gross Margin | -30.10% |
| Net Profit Margin | -550.86% |
| Debt/Equity Ratio | -47.0% |
How did ADMP perform over the long term?
See historical performance and comparison